Alto NeuroscienceANRO stock score: 36/100
$26.51 · +2.32% · Scored Nov 19, 2026
- Technical
- 53
- Fundamental
- 32
- News
- 57
The reading
Alto Neuroscience (ANRO) scores 36 out of 100, which reads bearish, higher than 13% of Healthcare stocks and 14% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 32, technicals 53.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Quality (Annual) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 53 and contrarian oscillators 49.
News sentiment is neutral at 57; it is shown, not counted in the composite.
Since Aug 23, 2026 the composite has ranged from 34 to 52, and it is down 15 points over the period.
About Alto Neuroscience
Alto Neuroscience (ANRO) is a clinical-stage biopharmaceutical company developing treatments for mental health conditions using a precision psychiatry approach. It uses biomarkers from EEG brain activity, cognitive tests, wearable devices and other data to identify which patients are most likely to respond to each drug. Its pipeline includes ALTO-100, being studied in bipolar depression, and ALTO-300, being studied as an add-on treatment for major depressive disorder in patients selected by an EEG biomarker. It also has ALTO-101 for cognitive impairment associated with schizophrenia, which has received Fast Track designation, ALTO-203 for depression with prominent anhedonia, and ALTO-207, a combination therapy for treatment-resistant depression. The company has no product revenue and funds its research mainly with cash from stock sales.
Alto competes with larger drugmakers that sell or are developing treatments for depression, bipolar disorder and schizophrenia, such as Johnson & Johnson, AbbVie and Bristol Myers Squibb, along with other biotech companies working in neuropsychiatry. Its edge rests on a biomarker platform and data set that it uses to match patients to drugs, along with a pipeline of several candidates. Investors who follow ANRO stock tend to watch data readouts from its mid-stage trials and whether biomarker-selected patients respond better than others. Plans for late-stage development are closely followed. Cash runway, potential partnerships and share dilution are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward ANRO’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
32Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.
Return on Equity (ROE) measures how efficiently a company generates profits from shareholder equity.
Return on Assets (ROA) shows how efficiently a company uses its assets to generate profit.
27 weighted scorers; 12 had no data today and are left out rather than counted as zero.
Technical · daily
53Pulling it up
Where the close sits against its 50-day EMA.
Performance versus SPY compares the stock's returns to the S&P 500 index.
The price change over the last 52 weeks.
Holding it back
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
Simple Moving Average (10-period) smooths price action over 10 periods.
SPY SMA 20 measures the S&P 500 (SPY) position relative to its 20-period moving average.
61 weighted scorers; 4 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 57
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 45 | 1 |
| Daily | 53 | 3 |
| Weekly | 56 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 36 |
| Nov 18, 2026 | 36 |
| Nov 17, 2026 | 34 |
| Nov 16, 2026 | 37 |
| Nov 15, 2026 | 37 |
| Nov 14, 2026 | 38 |
| Nov 13, 2026 | 38 |
| Nov 12, 2026 | 36 |
| Nov 11, 2026 | 51 |
| Nov 10, 2026 | 49 |
| Nov 7, 2026 | 44 |
| Nov 6, 2026 | 44 |
| Nov 5, 2026 | 40 |
| Nov 4, 2026 | 44 |
| Nov 3, 2026 | 44 |
| Nov 2, 2026 | 43 |
| Nov 1, 2026 | 42 |
| Oct 30, 2026 | 42 |
| Oct 29, 2026 | 45 |
| Oct 28, 2026 | 43 |
| Oct 27, 2026 | 44 |
| Oct 26, 2026 | 41 |
| Oct 25, 2026 | 41 |
| Oct 24, 2026 | 41 |
| Oct 23, 2026 | 41 |
| Oct 22, 2026 | 41 |
| Oct 21, 2026 | 43 |
| Oct 20, 2026 | 45 |
| Oct 19, 2026 | 42 |
| Oct 18, 2026 | 41 |
| Oct 17, 2026 | 41 |
| Oct 16, 2026 | 41 |
| Oct 15, 2026 | 42 |
| Oct 14, 2026 | 42 |
| Oct 13, 2026 | 41 |
| Oct 12, 2026 | 44 |
| Oct 11, 2026 | 44 |
| Oct 10, 2026 | 44 |
| Oct 9, 2026 | 44 |
| Oct 8, 2026 | 44 |
| Oct 7, 2026 | 43 |
| Oct 6, 2026 | 43 |
| Oct 5, 2026 | 43 |
| Oct 4, 2026 | 44 |
| Oct 3, 2026 | 44 |
| Oct 2, 2026 | 44 |
| Oct 1, 2026 | 43 |
| Sep 30, 2026 | 43 |
| Sep 29, 2026 | 45 |
| Sep 28, 2026 | 44 |
| Sep 27, 2026 | 44 |
| Sep 26, 2026 | 44 |
| Sep 25, 2026 | 44 |
| Sep 24, 2026 | 45 |
| Sep 23, 2026 | 46 |
| Sep 22, 2026 | 48 |
| Sep 21, 2026 | 47 |
| Sep 20, 2026 | 47 |
| Sep 19, 2026 | 47 |
| Sep 18, 2026 | 47 |
| Sep 17, 2026 | 48 |
| Sep 16, 2026 | 46 |
| Sep 15, 2026 | 46 |
| Sep 14, 2026 | 48 |
| Sep 13, 2026 | 48 |
| Sep 12, 2026 | 48 |
| Sep 11, 2026 | 48 |
| Sep 10, 2026 | 47 |
| Sep 9, 2026 | 48 |
| Sep 8, 2026 | 50 |
| Sep 7, 2026 | 50 |
| Sep 6, 2026 | 50 |
| Sep 5, 2026 | 50 |
| Sep 4, 2026 | 51 |
| Sep 2, 2026 | 51 |
| Sep 1, 2026 | 50 |
| Aug 31, 2026 | 50 |
| Aug 30, 2026 | 49 |
| Aug 29, 2026 | 49 |
| Aug 28, 2026 | 49 |
| Aug 27, 2026 | 51 |
| Aug 26, 2026 | 51 |
| Aug 25, 2026 | 51 |
| Aug 24, 2026 | 52 |
| Aug 23, 2026 | 51 |
Key facts
- Market cap
- $1.1B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 1.45
- Risk grade (1–10)
- 10
- Next earnings
- Nov 10, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| VOR Vor Biopharma | $1.1B | 43 |
| NKTR Nektar Therapeutics | $1.1B | 27 |
| INBX Inhibrx Biosciences | $1.1B | 38 |
| DRTS Alpha Tau Medical | $1.0B | 30 |
| OMER Omeros | $1.0B | 57 |
| JBIO Jade Biosciences | $1.0B | 36 |
Questions
What is ANRO's stock rating today?
ANRO scores 36/100 (Bearish) as of Nov 19, 2026: technical 53, fundamental 32, and news sentiment 57, which is shown but not counted. Scores are recomputed every night.
What does Alto Neuroscience do?
Alto Neuroscience (ANRO) is a clinical-stage biopharmaceutical company developing treatments for mental health conditions using a precision psychiatry approach. It uses biomarkers from EEG brain activity, cognitive tests, wearable devices and other data to identify which patients are most likely to respond to each drug.
Is ANRO stock a buy?
The score is not a buy or sell recommendation. A 36 says the technical and fundamental signals we measure lean bearish today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the ANRO score calculated?
88 weighted scorers feed it today: 27 fundamental, scored against Healthcare ranges, and 61 technical on the daily chart, with 3 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/anro/"><img src="https://stocksscores.com/stocks/anro/badge.svg" alt="ANRO stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/anro/)